CTOR Stock Analysis: Buy, Sell, or Hold?
CTOR - Citius Oncology, Inc. Common Stock
$0.70
0.01 (2.00%)
▲
5d:
-0.58%
30d:
+2.62%
90d:
+4.41%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 11, 2026
27d
Get Alerted When CTOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CTOR shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: CTOR shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: CTOR is currently trading at $0.70, which is considered fair relative to its 30-day fair value range of $0.66 to $0.73. From a valuation perspective, the stock is trading at a premium (Forward PE: 7.0) compared to its historical average (3.4). At these levels, the market is pricing in 27.3% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, CTOR is in a downtrend. Immediate support is located at $0.66, while resistance sits at $0.85.
Market Sentiment: CTOR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.00 (+467.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CTOR is in a downtrend. Immediate support is located at $0.66, while resistance sits at $0.85.
Market Sentiment: CTOR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.00 (+467.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.66 -
$0.73
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
78.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 467.5% below Wall St target ($4.00)
- BEARISH: Market expects 27.3% growth - appears too optimistic based on history
Trading Range Analysis
30-Day Trading Range
$0.66 -
$0.73
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.66
Resistance Level
$0.85
Current Trend
Downtrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.05
Wall Street Target
$4.00
(+467.5%)
Valuation Premium vs History
+27.3% premium
PE vs Historical
7.1 vs 3.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+27.3%
(market-implied from PE analysis)
1-Year Target
$0.90
(+27%)
2-Year Target
$1.14
(+62%)
3-Year Target
$1.45
(+106%)
3-Yr Target (if PE normalizes)
(PE: 7→3)
PE COMPRESSION
$0.70
(-1%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: July 14, 2026 12:37 AM ET
Data refreshes hourly during market hours. Next update: 1:37 AM
Data refreshes hourly during market hours. Next update: 1:37 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTOR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 51 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |